Treating patients with lupus with B-cell depletion

Lupus

Volumn 17, Issue 5 SPEC. ISS., 2008, Pages 400-404

  Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATACICEPT; BELIMUMAB; BRONCHODILATING AGENT; CD20 ANTIBODY; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; HYDROCORTISONE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ALBUMIN BLOOD LEVEL; B LYMPHOCYTE; BRONCHOSPASM; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 44849121063     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308090024     Document Type: Review

References (27)

1. Anderson, KC, Bates, MP, Slaughenhoupt, BL, et al. Expression of human B-cell-associated antigens on leukemias and lymphomas: a model of human B-cell differentiation. Blood 1984; 63: 1424-1433.
2. Tedder, TF, Boyd, AW, Freedman, AS, et al. The B-cell surface molecule B1 is functionally linked with B-cell activation and differentiation. J Immunol 1985; 135: 973-979.
3. Thompson, JS, Bixler, SA, Qian, F, et al. BAAF-R, a novel TNF receptor that specifically interacts with BAAF. Science 2001; 293: 2108-2111.
4. Reff, ME, Carner, K, Chambers, KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
5. Alas, S, Ng, CP, Bonavida, B. Rituximab modifies the cisplatin- mitochondrial signalling pathway, resulting in apoptosis in cisplatin non-Hodgkins lymphoma. Clin Cancer Res 2002; 8: 836-845.
6. Leandro, MJ, Edwards, JC, Cambridge, G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
7. Hay, EM, Bacon, PA, Gordon, C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-458.
8. Leandro, MJ, Cambridge, G, Edwards, JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542-1545.
9. Ng, KP, Leandro, MJ, Edwards, JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942-945.
10. Ng, KP, Cambridge, G, Leandro, MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66: 1259-1262.
11. Looney, RJ, Anolik, JH, Campbell, D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
12. Anolik, JH, Campbell, D, Felgar, RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459.
13. Anolik, JH, Barnard, J, Cappione, A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
14. Sfikakis, PP, Boletis, JN, Lionaki, S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513.
15. Gunnarsson, I, Sundelin, B, Jonsdottir, T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272.
16. Tanaka, Y, Yamanoto, K, Takeuchi, T, et al. A multicenter-phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2001; 17: 191-197.
17. Tokunaga, M, Saito, K, Kawabta, D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
18. Jonsdottiur, T, Gunnarsson, I, Risseada, A, Nenriksson, EW, Klareskog, L, van Vollenhoven, RF. Treatment of refractory SLE with rituximab plus cyclophosphamide:clinical effects, serological changes and predictors of response Ann Rheum Dis 2008; 67: 330-334.
19. Tedder, TF, Tuscano, J, Sato, S, Kehrl, JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481-504.
20. Dorner, T, Kaufmann, J, Wegener, WA, Teoh, N, Goldenberg, DM, Burmester, GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74. [This is the first trial using B cell depletion with a humanized anti CD-22 antibody in the treatment of systemic lupus erythematosus. Clinical efficacy and good tolerance probably related with a most favourable immunogenity profile are reported.].
21. Jacobi, AM, Goldenberg, DM, Hiepe, FT, et al. Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis 2007 [Epub ahead of print].
22. Moore, PA, Belvedere, O, Orr, A, et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
23. Huard, B, Schneider, P, Mauri, D, et al. T cell costimulation by the TNF ligand BAAF. J Immunol 2001; 167: 6225-6231.
24. Roschke, V, Sosnovtseva, S, Ward, CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.
25. Stohl, W, Metyas, S, Tan, SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
26. Ju, S, Zhang, D, Wang, Y, et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131-1137.
27. Furie, R, Stohl, W, Ginzler, E, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003; 48: S377.